Canine arthritis is a degenerative condition that results in inflammation of one or more joints and progresses over time if left untreated. The most commonly affected joints include the knee, elbow, shoulder, hip and spinal column. There are various causes of arthritis in dogs such as traumatic injuries, obesity, failure of proper bone development and many others. There are several types of canine arthritis but the most common is osteoarthritis. It affects 1 in 5 adult dogs. The prevalence of osteoarthritis increases with the age of canines. Its a chronic disease characterized by the loss of cartilage. It also includes other abnormalities such as osteophytosis in response to inflammation and pain.
The canine arthritis treatment types include non-steroidal anti-inflammatory medications (NSAIDs), opioids and stem cell Canine Arthritis Treatment. Non-steroidal anti-inflammatory Canine Arthritis Treatment are used to control pain and inflammation associated with arthritis. They are most commonly used canine arthritis treatment drugs. NSAIDs are used to treat mild to moderate pain by reducing the production of prostaglandins, which is involved with inflammation and discomfort. Several non-steroidal anti-inflammatory medications approved for canine arthritis treatment are Ketaprofen, Carprofen, Deracoxib, and Rimadyl, among others. Opioids are another class of pain relief medication for canine arthritis treatment, which includes Tramadol, Tapentadol, and buprenorphine, among others. Opioids work by acting through the central opioid receptors. They are used to treat moderate to severe as well as chronic pain associated with arthritis. The stem cell therapy is a new treatment option for canine arthritis treatment. The stem cell Canine Arthritis Treatment is usually performed as canine arthritis treatment using either autologous stem cells or allogeneic stem cells Canine Arthritis Treatment. In the stem cell canine arthritis treatment, the adult stem cells are harvested from canine’s fat tissues and injected into the affected joints. The stem cell Canine Arthritis Treatment has improved the quality of life of canines by reducing pain and increasing mobility and has shown 85% success rate within 5 months of canine arthritis treatment.
In terms of revenue, the global canine arthritis treatment market is projected to expand at a CAGR of 4.4% during the forecast period and is expected to be valued at US$ 3,051.8 Mn by the end of 2028. The Asia region is expected to witness siginificant growth in Canine Arthritis Treatment market.
The global canine arthritis treatment market is segmented into seven major regions: North America, Latin America, Europe, Asia Pacific (Asia-Pacific excluding Japan), Japan and Middle East & Africa (MEA). In terms of value, North America Canine Arthritis Treatment is expected to be the dominant regional market in canine arthritis treatment by 2018 end and is expected to expand with lucrative CAGR over the forecast period. Europe and Asia Pacific excluding Japan are expected to be the fast-growing markets in terms of revenue growth in the global canine arthritis treatment market, registering healthy CAGRs over the forecast period.
In North America, the U.S. is the dominant market for canine arthritis treatment due to increased consumer spending on pets. Over the past few decades, it has been noted that the U.S. vet care spending has almost doubled owing to increase in awareness regarding the diseases in animals and accessibility of treatment and diagnostic methods for various chronic diseases. Increasing vet care spending is expected to directly impact the need for better treatment therapies and drugs, which in turn creates high growth opportunities for players operating in the canine arthritis treatment market over the forecast period. As per the American Pet Products Association, about US$ 7.4 Bn was spent on vet care in canines in 2017 in the U.S. According to the APPA (American Pet Products Association), in 2017, the pet population in the U.S. grew to 393.3 million, accounting for 89.7 million dogs.
The second dominant market in canine arthritis treatment is Germany owing to the rise in prevalence of chronic diseases in animals, particularly dogs. It has been found that with growing age of pets, the prevalence of diseases such as allergies, lower appetite, reduced energy, arthritis, lameness, dysplasia and behavioural anxieties increases, especially in dogs and cats. This growth in terms of pet adoption in European countries and increasing number of pets suffering from arthritis is likely to boost the growth of canine arthritis treatment in Europe. This has been driving the demand for innovative therapies and drugs in Canine Arthritis Treatment, such as stem cell Canine Arthritis Treatment and arthritis drugs – NSAIDs and opioids. Canine arthritis treatment/drugs in Germany have taken initiatives to incentivize innovation in the field of veterinary treatment in order to address the urgent need of better veterinary care and to combat rapid growing prevalence of animal diseases. Additionally, increasing expenditure on vet care in high economic European countries such as Germany, France and the U.K. also boosts the growth of the market for canine arthritis treatment. As per the American Pet Products Association, about US$ 6.1 Bn was spent on vet care in 2017 in Europe.
Increasing pet adoption in China and India is expected to drive the growth of the canine arthritis treatment market in Asia-Pacific. In Japan and the Middle East and Africa, the population of dogs is decreasing due to poor vet care facilities, which is expected to hamper the growth of canine arthritis treatment market to some extent.
MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.Get A Free Custom Research Quote